Global Alzheimer's Disease Pricing & Reimbursement Analysis, 2026-2035

Description

Alzheimer’s disease is the leading cause of dementia worldwide and represents one of the most significant healthcare challenges associated with aging populations. The disease is characterized by progressive cognitive decline, memory impairment, behavioral changes, and loss of functional independence. The increasing prevalence of Alzheimer’s disease is creating substantial clinical and economic burdens for healthcare systems globally. As novel disease-modifying therapies enter the market, pricing and reimbursement considerations are becoming critical determinants of patient access, commercial success, and healthcare sustainability.

Pricing and reimbursement analysis provides strategic insights into market access requirements, payer expectations, reimbursement policies, health technology assessment processes, value-based pricing strategies, and patient affordability considerations. The growing complexity of Alzheimer’s disease treatment, particularly with the introduction of advanced biologics and disease-modifying therapies, is increasing demand for comprehensive reimbursement intelligence among pharmaceutical companies, healthcare providers, policymakers, and payer organizations.

Market Drivers

Emergence of Disease-Modifying Therapies

One of the most significant drivers of market growth is the commercialization of disease-modifying therapies designed to slow the progression of Alzheimer’s disease. Unlike traditional symptomatic treatments, these therapies aim to address underlying disease pathology and may offer long-term clinical benefits.

The introduction of innovative therapies is increasing the importance of reimbursement evaluations, value assessments, and pricing negotiations between manufacturers and healthcare systems. Recent health economic studies have highlighted the growing focus on value-based pricing models for emerging Alzheimer’s disease therapies across both developed and developing healthcare markets.

Increasing Healthcare Expenditure on Dementia Care

The economic burden associated with Alzheimer’s disease continues to rise due to increasing prevalence, aging populations, and growing long-term care requirements. Governments and healthcare organizations are allocating greater resources toward dementia management, diagnosis, treatment, and patient support programs.

Growing healthcare expenditure is encouraging the development of structured reimbursement frameworks capable of supporting access to innovative therapies while maintaining budget sustainability.

Expansion of Value-Based Healthcare Models

Healthcare systems are increasingly adopting value-based reimbursement approaches that link pricing decisions to clinical outcomes, patient benefits, and long-term economic impact.

For Alzheimer’s disease therapies, reimbursement decisions are increasingly influenced by evidence demonstrating improvements in cognitive function, quality of life, disease progression, and healthcare resource utilization. Value-based pricing models are expected to become increasingly important as more advanced therapies enter the market.

Growth of Health Technology Assessment Programs

Health technology assessment (HTA) organizations are playing a growing role in evaluating the clinical effectiveness, economic value, and budget impact of Alzheimer’s disease therapies.

The increasing use of cost-effectiveness analyses, quality-adjusted life year assessments, and budget impact models is supporting evidence-based reimbursement decisions and driving demand for pricing and reimbursement intelligence.

Market Restraints

High Cost of Innovative Therapies

Disease-modifying therapies for Alzheimer’s disease often involve complex development programs, advanced manufacturing processes, and extensive clinical evaluation. These factors contribute to elevated treatment costs and create challenges for healthcare payers.

High therapy costs may lead to reimbursement restrictions, patient eligibility requirements, or extended pricing negotiations before broad market access can be achieved.

Limited Long-Term Outcomes Data

Many recently introduced therapies have relatively limited long-term real-world evidence regarding durability of clinical benefits, healthcare savings, and long-term patient outcomes.

Payers frequently require additional evidence before providing widespread reimbursement approval, potentially delaying patient access and market adoption.

Variability in Global Reimbursement Systems

Pricing and reimbursement policies differ substantially across countries. Variations in healthcare funding structures, regulatory requirements, HTA methodologies, and payer priorities create challenges for manufacturers seeking global commercialization.

These differences often require region-specific market access and reimbursement strategies.

Technology and Segment Insights

The global Alzheimer’s disease pricing and reimbursement analysis market can be segmented by therapy type, reimbursement model, payer type, distribution channel, end user, and geography.

By therapy type, the market includes symptomatic therapies, disease-modifying therapies, monoclonal antibodies, small-molecule therapies, combination therapies, and emerging precision medicine treatments. Disease-modifying therapies represent the fastest-growing segment due to increasing regulatory approvals and growing healthcare interest in slowing disease progression.

By reimbursement model, the market includes public reimbursement programs, private insurance coverage, value-based reimbursement agreements, outcomes-based contracts, risk-sharing arrangements, orphan and specialty drug reimbursement frameworks, and patient assistance programs. Value-based and outcomes-based reimbursement models are expected to gain substantial importance as healthcare systems seek to balance innovation with affordability.

By payer type, the market includes government healthcare agencies, national health systems, private insurance providers, employer-sponsored health plans, and specialized reimbursement organizations. Government-funded healthcare systems represent a significant share of reimbursement decision-making in major pharmaceutical markets.

By distribution channel, the market includes hospital pharmacies, specialty pharmacies, retail pharmacies, integrated healthcare systems, and direct distribution networks. Specialty pharmacies are expected to play an increasingly important role due to the complexity of managing advanced Alzheimer’s disease therapies.

By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, payer organizations, reimbursement consultants, health technology assessment agencies, academic institutions, and policymakers. Pharmaceutical and biotechnology companies represent a major end-user segment due to increasing focus on market access planning and commercialization strategies.

Technological advancements are transforming pricing and reimbursement analysis through artificial intelligence, predictive analytics, health economic modeling, real-world evidence platforms, electronic health records, and integrated healthcare databases. These technologies support more accurate evaluations of treatment value, patient outcomes, healthcare utilization, and budget impact.

The increasing availability of real-world evidence is expected to strengthen reimbursement negotiations by providing additional insights into long-term treatment effectiveness and healthcare system benefits. Cost-effectiveness analyses are becoming increasingly important in determining acceptable pricing levels and reimbursement eligibility for novel Alzheimer’s disease therapies.

Geographically, North America represents the largest market due to advanced healthcare infrastructure, significant dementia-related healthcare spending, established reimbursement systems, and strong therapeutic development activity. Europe maintains a substantial market position supported by comprehensive HTA frameworks and government-funded healthcare systems. Asia-Pacific is expected to experience rapid growth owing to increasing healthcare investment, expanding insurance coverage, rising dementia prevalence, and healthcare policy modernization. Latin America and the Middle East & Africa are gradually strengthening reimbursement systems and healthcare access initiatives for neurological disorders.

Competitive and Strategic Outlook

The competitive landscape is evolving rapidly as pharmaceutical and biotechnology companies prepare to commercialize innovative Alzheimer’s disease therapies. Organizations are investing heavily in health economics and outcomes research, payer engagement strategies, market access planning, and reimbursement optimization initiatives.

Strategic collaborations among drug manufacturers, healthcare providers, payer organizations, patient advocacy groups, and research institutions are becoming increasingly important. These partnerships support evidence generation, value demonstration, reimbursement negotiations, and patient access programs.

Manufacturers are focusing on demonstrating meaningful clinical outcomes and long-term economic benefits to secure favorable reimbursement decisions. Real-world evidence generation, outcomes-based agreements, and value-based pricing frameworks are expected to become increasingly common as competition intensifies within the Alzheimer’s disease treatment landscape.

As additional disease-modifying therapies reach commercialization, pricing strategies, reimbursement pathways, and market access capabilities will become critical differentiators among market participants.

Conclusion

The global Alzheimer’s disease pricing and reimbursement analysis market is expected to experience strong growth through 2031, supported by the emergence of disease-modifying therapies, increasing dementia-related healthcare expenditure, expanding HTA programs, and growing adoption of value-based healthcare models. Pricing and reimbursement strategies will play a pivotal role in determining patient access and commercial success for innovative Alzheimer’s disease treatments. Although challenges related to therapy costs, evidence requirements, and reimbursement variability remain, ongoing advancements in health economics, real-world evidence generation, and value-based pricing approaches are expected to strengthen market access opportunities and improve treatment accessibility for patients worldwide.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

Product Code: KSI-008837

1. Executive Summary

1.1 Report Overview
1.2 Key Findings and Strategic Insights
1.3 Global Pricing and Reimbursement Landscape Snapshot
1.4 Alzheimer's Disease Market Access Outlook
1.5 Key Reimbursement Trends Across Major Markets
1.6 Executive Recommendations for Stakeholders

2. Disease & Epidemiology Analysis

2.1 Introduction to Alzheimer's Disease
2.2 Disease Burden and Public Health Impact
2.3 Pathophysiology and Disease Progression
2.4 Classification of Alzheimer's Disease
- 2.4.1 Preclinical Alzheimer's Disease
- 2.4.2 Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
- 2.4.3 Mild Alzheimer's Dementia
- 2.4.4 Moderate Alzheimer's Dementia
- 2.4.5 Severe Alzheimer's Dementia
2.5 Global Epidemiology Overview
- 2.5.1 Prevalence Analysis
- 2.5.2 Incidence Analysis
- 2.5.3 Mortality Analysis
- 2.5.4 Disease Burden by Age Group
- 2.5.5 Disease Burden by Gender
2.6 Biomarker Landscape and Diagnostic Evolution
- 2.6.1 Amyloid Biomarkers
- 2.6.2 Tau Biomarkers
- 2.6.3 Neurodegeneration Biomarkers
2.7 Economic Burden of Alzheimer's Disease
2.8 Unmet Clinical and Access Needs

3. Market Dynamics

3.1 Market Overview
3.2 Market Drivers
- 3.2.1 Rising Aging Population
- 3.2.2 Increasing Disease Awareness and Diagnosis Rates
- 3.2.3 Emergence of Disease-Modifying Therapies
- 3.2.4 Expansion of Biomarker-Based Diagnostics
- 3.2.5 Government Support for Dementia Care Programs
3.3 Market Restraints
- 3.3.1 High Treatment Costs
- 3.3.2 Reimbursement Challenges
- 3.3.3 Diagnostic Infrastructure Limitations
- 3.3.4 Safety Monitoring Requirements
3.4 Market Opportunities
- 3.4.1 Expansion of Early Diagnosis Programs
- 3.4.2 Value-Based Reimbursement Models
- 3.4.3 Emerging Market Access Expansion
- 3.4.4 Digital Health and Cognitive Assessment Tools
3.5 Market Challenges
3.6 Porter's Five Forces Analysis
3.7 PESTLE Analysis

4. Commercial & Market Access Analysis

4.1 Market Access Framework for Alzheimer's Disease Therapies
4.2 Pricing Landscape Assessment
- 4.2.1 Branded Therapies Pricing Analysis
- 4.2.2 Generic Therapies Pricing Analysis
- 4.2.3 Regional Pricing Variations
4.3 Reimbursement Framework Analysis
- 4.3.1 Public Reimbursement Systems
- 4.3.2 Private Reimbursement Systems
- 4.3.3 Hybrid Reimbursement Models
4.4 Health Technology Assessment (HTA) Impact
- 4.4.1 Cost-Effectiveness Evaluation
- 4.4.2 Budget Impact Assessment
- 4.4.3 Real-World Evidence Requirements
4.5 Payer Perspectives and Coverage Criteria
4.6 Patient Access and Affordability Assessment
4.7 Market Access Barriers and Mitigation Strategies
4.8 Value-Based Pricing and Outcome-Based Agreements

5. Innovation & Pipeline Landscape

5.1 Pipeline Overview
5.2 Pipeline Distribution by Development Phase
- 5.2.1 Discovery and Preclinical Candidates
- 5.2.2 Phase I Candidates
- 5.2.3 Phase II Candidates
- 5.2.4 Phase III Candidates
5.3 Pipeline Analysis by Mechanism of Action
- 5.3.1 Anti-Amyloid Therapies
- 5.3.2 Anti-Tau Therapies
- 5.3.3 Neuroprotective Therapies
- 5.3.4 Neuroinflammation Modulators
- 5.3.5 Synaptic Function Modulators
- 5.3.6 Metabolic and Mitochondrial Therapies
5.4 Pipeline Analysis by Modality
- 5.4.1 Monoclonal Antibodies
- 5.4.2 Small Molecules
- 5.4.3 Cell-Based Therapies
- 5.4.4 Gene Therapies
- 5.4.5 RNA-Based Therapeutics
5.5 Clinical Trial Landscape
5.6 Licensing, Partnerships, and Collaborations
5.7 Emerging Technologies and Future Innovations

6. Treatment Landscape

6.1 Current Standard of Care
6.2 Treatment Guidelines Overview
6.3 Approved Pharmacological Therapies
- 6.3.1 Cholinesterase Inhibitors
- 6.3.2 NMDA Receptor Antagonists
- 6.3.3 Anti-Amyloid Monoclonal Antibodies
6.4 Non-Pharmacological Interventions
6.5 Treatment Algorithm Analysis
6.6 Comparative Assessment of Approved Therapies
6.7 Patient Journey Analysis
6.8 Future Treatment Paradigm Shifts

7. Global Alzheimer's Disease Pricing & Reimbursement Analysis Size & Forecast Analysis

7.1 Global Market Overview
7.2 Historical Market Analysis (2020-2024)
7.3 Current Market Assessment (2025)
7.4 Market Forecast (2026-2035)
7.5 Pricing Trend Analysis
7.6 Reimbursement Trend Analysis
7.7 Scenario-Based Forecast Modeling
7.8 Market Attractiveness Analysis

8. Global Alzheimer's Disease Pricing & Reimbursement Analysis Segmentation

8.1 By Therapy Type
- 8.1.1 Symptomatic Treatments
- 8.1.2 Disease-Modifying Therapies
- 8.1.3 Others
8.2 By Indication
- 8.2.1 Mild Cognitive Impairment Due to Alzheimer's Disease
- 8.2.2 Mild & Moderate Alzheimer's Disease
- 8.2.3 Severe Alzheimer's Disease
8.3 By End User
- 8.3.1 Hospitals
- 8.3.2 Specialty Neurology Clinics
- 8.3.3 Others
8.4 By Distribution Channel
- 8.4.1 Hospital Pharmacies
- 8.4.2 Retail Pharmacies & Specialty Pharmacies
- 8.4.3 Online Pharmacies

9. Geographical Analysis (Regional Level)

9.1 North America
- 9.1.1 Market Size and Growth Analysis
- 9.1.2 Demand Drivers
- 9.1.3 Regional Regulatory Overview
- 9.1.4 Reimbursement Environment
- 9.1.5 Competitive Intensity Assessment
9.2 Europe
- 9.2.1 Market Size and Growth Analysis
- 9.2.2 Demand Drivers
- 9.2.3 Regional Regulatory Overview
- 9.2.4 Reimbursement Environment
- 9.2.5 Competitive Intensity Assessment
9.3 Asia-Pacific
- 9.3.1 Market Size and Growth Analysis
- 9.3.2 Demand Drivers
- 9.3.3 Regional Regulatory Overview
- 9.3.4 Reimbursement Environment
- 9.3.5 Competitive Intensity Assessment
9.4 Latin America
- 9.4.1 Market Size and Growth Analysis
- 9.4.2 Demand Drivers
- 9.4.3 Regional Regulatory Overview
- 9.4.4 Reimbursement Environment
- 9.4.5 Competitive Intensity Assessment
9.5 Middle East & Africa
- 9.5.1 Market Size and Growth Analysis
- 9.5.2 Demand Drivers
- 9.5.3 Regional Regulatory Overview
- 9.5.4 Reimbursement Environment
- 9.5.5 Competitive Intensity Assessment

10. Key Countries Analysis

10.1 United States
- 10.1.1 Market Size Analysis
- 10.1.2 Epidemiology Assessment
- 10.1.3 Regulatory Framework
- 10.1.4 Reimbursement Landscape
- 10.1.5 Key Company and Product Presence
10.2 Canada
- 10.2.1 Market Size Analysis
- 10.2.2 Epidemiology Assessment
- 10.2.3 Regulatory Framework
- 10.2.4 Reimbursement Landscape
- 10.2.5 Key Company and Product Presence
10.3 Germany
- 10.3.1 Market Size Analysis
- 10.3.2 Epidemiology Assessment
- 10.3.3 Regulatory Framework
- 10.3.4 Reimbursement Landscape
- 10.3.5 Key Company and Product Presence
10.4 United Kingdom
- 10.4.1 Market Size Analysis
- 10.4.2 Epidemiology Assessment
- 10.4.3 Regulatory Framework
- 10.4.4 Reimbursement Landscape
- 10.4.5 Key Company and Product Presence
10.5 France
- 10.5.1 Market Size Analysis
- 10.5.2 Epidemiology Assessment
- 10.5.3 Regulatory Framework
- 10.5.4 Reimbursement Landscape
- 10.5.5 Key Company and Product Presence
10.6 Italy
- 10.6.1 Market Size Analysis
- 10.6.2 Epidemiology Assessment
- 10.6.3 Regulatory Framework
- 10.6.4 Reimbursement Landscape
- 10.6.5 Key Company and Product Presence
10.7 Spain
- 10.7.1 Market Size Analysis
- 10.7.2 Epidemiology Assessment
- 10.7.3 Regulatory Framework
- 10.7.4 Reimbursement Landscape
- 10.7.5 Key Company and Product Presence
10.8 China
- 10.8.1 Market Size Analysis
- 10.8.2 Epidemiology Assessment
- 10.8.3 Regulatory Framework
- 10.8.4 Reimbursement Landscape
- 10.8.5 Key Company and Product Presence
10.9 Japan
- 10.9.1 Market Size Analysis
- 10.9.2 Epidemiology Assessment
- 10.9.3 Regulatory Framework
- 10.9.4 Reimbursement Landscape
- 10.9.5 Key Company and Product Presence
10.10 India
- 10.10.1 Market Size Analysis
- 10.10.2 Epidemiology Assessment
- 10.10.3 Regulatory Framework
- 10.10.4 Reimbursement Landscape
- 10.10.5 Key Company and Product Presence
10.11 South Korea
- 10.11.1 Market Size Analysis
- 10.11.2 Epidemiology Assessment
- 10.11.3 Regulatory Framework
- 10.11.4 Reimbursement Landscape
- 10.11.5 Key Company and Product Presence
10.12 Australia
- 10.12.1 Market Size Analysis
- 10.12.2 Epidemiology Assessment
- 10.12.3 Regulatory Framework
- 10.12.4 Reimbursement Landscape
- 10.12.5 Key Company and Product Presence
10.13 Brazil
- 10.13.1 Market Size Analysis
- 10.13.2 Epidemiology Assessment
- 10.13.3 Regulatory Framework
- 10.13.4 Reimbursement Landscape
- 10.13.5 Key Company and Product Presence
10.14 Mexico
- 10.14.1 Market Size Analysis
- 10.14.2 Epidemiology Assessment
- 10.14.3 Regulatory Framework
- 10.14.4 Reimbursement Landscape
- 10.14.5 Key Company and Product Presence
10.15 Saudi Arabia
- 10.15.1 Market Size Analysis
- 10.15.2 Epidemiology Assessment
- 10.15.3 Regulatory Framework
- 10.15.4 Reimbursement Landscape
- 10.15.5 Key Company and Product Presence
10.16 South Africa
- 10.16.1 Market Size Analysis
- 10.16.2 Epidemiology Assessment
- 10.16.3 Regulatory Framework
- 10.16.4 Reimbursement Landscape
- 10.16.5 Key Company and Product Presence

11. Regulatory & Policy Landscape

11.1 Global Regulatory Overview
11.2 U.S. FDA Framework for Alzheimer's Disease Therapies
11.3 European Medicines Agency (EMA) Framework
11.4 Japan PMDA Regulatory Framework
11.5 India CDSCO Regulatory Framework
11.6 China NMPA Regulatory Framework
11.7 Health Technology Assessment Requirements
11.8 Pricing and Reimbursement Regulations
11.9 Orphan, Accelerated, and Priority Review Pathways
11.10 Emerging Policy Developments

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Competitive Benchmarking
12.3 Product Portfolio Assessment
12.4 Pricing Strategy Analysis
12.5 Reimbursement Strategy Analysis
12.6 Pipeline Competitiveness Assessment
12.7 Strategic Collaborations and Licensing Agreements
12.8 Mergers, Acquisitions, and Expansion Activities
12.9 SWOT Analysis of Leading Participants

13. Company Profiles

13.1 Eli Lilly and Company
- 13.1.1 Company Overview
- 13.1.2 Approved Products (Kisunla(R)/donanemab)
- 13.1.3 Key Indications
- 13.1.4 Alzheimer's Disease Pipeline Assets
- 13.1.5 Pricing and Reimbursement Strategy
- 13.1.6 Strategic Developments
13.2 Eisai Co., Ltd.
- 13.2.1 Company Overview
- 13.2.2 Approved Products (Leqembi(R)/lecanemab, Aricept(R)/donepezil)
- 13.2.3 Key Indications
- 13.2.4 Alzheimer's Disease Pipeline Assets
- 13.2.5 Pricing and Reimbursement Strategy
- 13.2.6 Strategic Developments
13.3 Biogen Inc.
- 13.3.1 Company Overview
- 13.3.2 Approved Products (Leqembi(R) collaboration, Aduhelm(R)/aducanumab)
- 13.3.3 Key Indications
- 13.3.4 Alzheimer's Disease Pipeline Assets
- 13.3.5 Pricing and Reimbursement Strategy
- 13.3.6 Strategic Developments
13.4 Ono Pharmaceutical Co., Ltd.
- 13.4.1 Company Overview
- 13.4.2 Approved Neurology Portfolio
- 13.4.3 Key Indications
- 13.4.4 Alzheimer's Disease Pipeline Assets
- 13.4.5 Pricing and Reimbursement Strategy
- 13.4.6 Strategic Developments
13.5 Teva Pharmaceutical Industries Ltd.
- 13.5.1 Company Overview
- 13.5.2 Approved Products (Donepezil Generic Portfolio)
- 13.5.3 Key Indications
- 13.5.4 CNS Pipeline Overview
- 13.5.5 Pricing and Reimbursement Strategy
- 13.5.6 Strategic Developments
13.6 Otsuka Pharmaceutical Co., Ltd.
- 13.6.1 Company Overview
- 13.6.2 Neurology Portfolio Overview
- 13.6.3 Key Indications
- 13.6.4 Alzheimer's Disease Pipeline Assets
- 13.6.5 Pricing and Reimbursement Strategy
- 13.6.6 Strategic Developments
13.7 Dr. Reddy's Laboratories Ltd.
- 13.7.1 Company Overview
- 13.7.2 Approved Products (Donepezil Generic Portfolio)
- 13.7.3 Key Indications
- 13.7.4 CNS Pipeline Overview
- 13.7.5 Pricing and Reimbursement Strategy
- 13.7.6 Strategic Developments
13.8 Olainfarm
- 13.8.1 Company Overview
- 13.8.2 CNS Product Portfolio
- 13.8.3 Key Indications
- 13.8.4 Pipeline Overview
- 13.8.5 Pricing and Reimbursement Strategy
- 13.8.6 Strategic Developments
13.9 Lundbeck A/S
- 13.9.1 Company Overview
- 13.9.2 Approved Products (Ebixa(R)/memantine, Cognition Portfolio)
- 13.9.3 Key Indications
- 13.9.4 Alzheimer's Disease Pipeline Assets
- 13.9.5 Pricing and Reimbursement Strategy
- 13.9.6 Strategic Developments
13.10 Midas Pharma GmbH
- 13.10.1 Company Overview
- 13.10.2 CNS and API Portfolio Overview
- 13.10.3 Alzheimer's Disease Related Offerings
- 13.10.4 Business Development Strategy
- 13.10.5 Pricing and Market Access Support Activities
- 13.10.6 Strategic Developments

14. Future Outlook

14.1 Future Market Evolution
14.2 Reimbursement Reform Outlook
14.3 Impact of Disease-Modifying Therapies
14.4 Biomarker-Driven Access Models
14.5 Emerging Competitive Dynamics
14.6 Investment Opportunities
14.7 Strategic Recommendations
14.8 Long-Term Market Forecast Scenario

15. Methodology

15.1 Research Objectives
15.2 Research Design
15.3 Primary Research Methodology
15.4 Secondary Research Methodology
15.5 Data Validation and Triangulation
15.6 Market Forecasting Approach
15.7 Pricing and Reimbursement Assessment Framework
15.8 Epidemiology Modeling Methodology
15.9 Pipeline Assessment Methodology
15.10 Limitations and Assumptions
15.11 Abbreviations and Definitions